H.C. Wainwright predicts the CIC drug’s annualized run rate surpasses $30 million.
Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.
Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.
ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.
Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.
Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.